Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06305247 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorIpsen
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 11 to 12 Eligibility criteria expanded, about 30 words · Study description expanded, about 3 words Show 2 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Study description expanded, about 3 words
  2. 3 versions Re-verified since Jun 29, 2026, no change to tracked fieldsv30-v32
  3. Enrollment reduced: 220 → 36 participants Trial status changed: Recruiting → Active, Not Recruiting · Study sites: 12 to 11v29 Show 2 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 12 to 11
  4. 14 versions Re-verified since Mar 31, 2025, no change to tracked fieldsv15-v28
  5. Site details revised at 1 of 12 sitesv14
Show 12 earlier versionsHide 12 earlier versions
  1. Site details revised at 1 of 12 sitesv13
  2. Site details revised at 1 of 12 sitesv12
  3. Site details revised at 4 of 12 sitesv11
  4. 2 versions Re-verified since Sep 30, 2024, no change to tracked fieldsv9-v10
  5. Site details revised at 2 of 12 sitesv8
  6. Site details revised at 1 of 12 sitesv7
  7. Site details revised at 1 of 12 sitesv6
  8. Re-verified, no change to tracked fieldsv5
  9. Study sites: 1 to 12v4
  10. Start date changed from estimate of Mar 15, 2024 to Apr 3, 2024v3
  11. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Mar 14, 2024 to Mar 15, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date: Mar 14, 2024 to Mar 15, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ipsen
46 trials monitored
See 4 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
and 1 more disease
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Trial Details
NCT Number NCT06305247
Lead Sponsor Ipsen
Conditions Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov